

Table 1: Tumour size at baseline

Tumour Characteristics	Active	Placebo	Total
Tumour size (mm)*			
N	75	75	150
Mean	4.47	4.00	4.23
St. Dev	1.61	1.56	1.59
Median	4	4	4
IQR, Range	IQR(3,5) R(2,11)	IQR(3,5) R(2,10)	IQR(3,5) R(2,11)
Location (N %)	75	75	150
Trunk	5 (6.7)	5 (6.7)	10 (6.7)
Face and Neck	41 (54.7)	39 (52.0)	80 (53.3)
Scalp	29 (38.7)	31 (41.3)	60 (40.0)
Limbs	0 (0)	0 (0)	0 (0)
Other	0 (0)	0 (0)	0 (0)
Appearance (N %)	75	75	150
Hairy	34 (45.3)	36 (48.0)	70 (46.7)
Non-hairy	40 (53.3)	39 (52.0)	79 (52.7)
Not applicable	1 (1.3)	0	1 (0.7)

15 participants enrolled onto cohort 2 had 10 tumours selected (5 from right hand side and 5 from the left hand side of the body). The diameters of the 150 tumours selected were measured by a ruler. As indicated by table 1, 75 tumours were treated with CT327 ointment and the remaining 75 with placebo ointment. The study investigator, study team and participants were all blinded to the which sides received treatment and placebo.

Table 2: Tumour measurements at baseline, week 4 and week 12 in cohort 2

		n	mean	95% CI	median	IQR	
OVERALL	height	150	0.74	(0.68, 0.81)	0.64	(0.47 , 0.91)	
	Baseline	surface area	150	28.62	(25.78, 31.47)	25.24	(15.50 , 35.78)
		volume	150	7.96	(6.36, 9.56)	4.66	(2.58 , 8.98)
		height	140	0.78	(0.71, 0.86)	0.66	(0.49 , 0.99)
	Week 4	surface area	140	29.20	(26.11, 32.28)	25.47	(15.15 , 37.82)
		volume	140	8.77	(6.80, 10.73)	5.01	(2.44 , 9.16)
		height	140	0.78	(0.71, 0.86)	0.66	(0.47 , 1.00)
	Week 12	surface area	140	29.18	(26.08, 32.28)	25.79	(15.74 , 38.32)
		volume	140	8.71	(6.75, 10.68)	4.80	(2.33 , 9.25)
height		75	0.74	(0.65, 0.84)	0.65	(0.46 , 0.93)	
ACTIVE	height	75	0.74	(0.65, 0.84)	0.65	(0.46 , 0.93)	
	Baseline	surface area	75	29.19	(25.28, 33.09)	26.49	(15.42 , 38.26)
		volume	75	8.12	(5.92, 10.33)	4.98	(2.57 , 9.40)
		height	70	0.79	(0.69, 0.90)	0.65	(0.46 , 1.01)
	Week 4	surface area	70	30.04	(25.87, 34.22)	27.71	(14.95 , 39.38)
		volume	70	8.99	(6.33, 11.65)	5.12	(2.26 , 11.41)
		height	70	0.79	(0.68, 0.89)	0.67	(0.46 , 1.02)
	Week 12	surface area	70	29.80	(25.63, 33.97)	26.99	(15.57 , 39.06)
		volume	70	8.83	(6.21, 11.47)	4.59	(1.95 , 10.92)
height		75	0.74	(0.65, 0.83)	0.62	(0.50 , 0.91)	
PLACEBO	height	75	0.74	(0.65, 0.83)	0.62	(0.50 , 0.91)	
	Baseline	surface area	75	28.06	(23.83, 32.29)	24.81	(16.44 , 34.54)
		volume	75	7.79	(5.42, 10.17)	4.38	(2.58 , 8.03)
		height	70	0.78	(0.67, 0.88)	0.68	(0.50 , 0.96)
	Week4	surface area	70	28.35	(23.72, 32.99)	25.24	(15.73 , 34.73)
		volume	70	8.54	(5.59, 11.49)	4.99	(2.48 , 7.90)
		height	70	0.78	(0.67, 0.89)	0.65	(0.50 , 0.99)
	Week 12	surface area	70	28.56	(23.87, 33.25)	25.52	(15.88 , 34.43)
		volume	70	8.59	(5.59, 11.59)	5.01	(2.48 , 8.26)

Tumour volume was measured on the predetermined identified tumours in each patient prior to randomisation and measured again and recorded on the same tumours at 4 and 12 weeks. Tumour measurements (mean of the three readings) have been reported descriptively as mean (standard deviation) median and IQR at baseline, 4 weeks and 12 weeks and by treatment received and overall.

Table 3: Tumour measurements of hairy tumours at baseline, week 4 and week 12 in cohort 2

		n	mean	95% CI	median	IQR	
ACTIVE	Baseline	height	34	0.87	(0.70, 1.04)	0.79	(0.52 , 1.15)
		surface area	34	34.53	(27.56, 41.49)	29.23	(19.46 , 48.04)
		volume	34	11.26	(6.96, 15.56)	6.03	(3.42 , 17.12)
	Week 4	height	32	0.94	(0.75, 1.13)	0.90	(0.52 , 1.38)
		surface area	32	35.39	(27.76, 43.02)	29.82	(19.54 , 49.16)
		volume	32	12.87	(7.68, 18.07)	6.30	(2.62 , 19.75)
	Week 12	height	32	0.93	(0.74, 1.12)	0.90	(0.50 , 1.31)
		surface area	32	34.83	(27.26, 42.40)	29.94	(19.97 , 48.83)
		volume	32	12.74	(7.62, 17.85)	7.08	(3.16 , 18.64)
PLACEBO	Baseline	height	36	0.84	(0.69, 0.99)	0.9	(0.52 , 1.04)
		surface area	36	36.39	(29.11, 43.66)	30.41	(23.40 , 43.01)
		volume	36	11.29	(6.84, 15.75)	7.05	(3.43 , 11.48)
	Week4	height	34	0.92	(0.74, 1.10)	0.85	(0.60 , 1.20)
		surface area	34	37.33	(29.38, 45.28)	30.58	(21.48 , 43.09)
		volume	34	12.93	(7.35, 18.50)	7.59	(3.71 , 13.45)
	Week 12	height	34	0.92	(0.74, 1.10)	0.76	(0.58 , 1.14)
		surface area	34	37.62	(29.60, 45.63)	30.59	(22.61 , 44.44)
		volume	34	12.91	(7.23, 18.58)	8.06	(2.79 , 12.62)

Table 4: Tumour measurements of non-hairy tumours at baseline, week 4 and week 12 in cohort 2

		n	mean	95% CI	median	IQR	
ACTIVE	Baseline	height	40	0.64	(0.70, 1.04)	0.54	(0.46 , 0.79)
		surface area	40	24.53	(27.56, 41.49)	22.22	(13.73 , 33.51)
		volume	40	5.46	(6.96, 15.56)	3.69	(1.79 , 6.60)
	Week 4	height	38	0.67	(0.75, 1.13)	0.61	(0.43 , 0.87)
		surface area	38	25.54	(27.76, 43.02)	21.71	(14.42 , 34.16)
		volume	38	5.72	(7.68, 18.07)	3.83	(1.83 , 6.57)
	Week 12	height	38	0.66	(0.74, 1.12)	0.59	(0.46 , 0.80)
		surface area	38	25.57	(27.26, 42.40)	21.76	(14.22 , 34.21)
		volume	38	5.56	(7.62, 17.85)	4.03	(1.93 , 6.10)
PLACEBO	Baseline	height	39	0.65	(0.69, 0.99)	0.58	(0.48 , 0.72)
		surface area	39	20.37	(29.11, 43.66)	18.52	(12.92 , 25.62)
		volume	39	4.56	(6.84, 15.75)	2.96	(1.89 , 5.79)
	Week4	height	36	0.64	(0.74, 1.10)	0.58	(0.46 , 0.75)
		surface area	36	19.88	(29.38, 45.28)	12.33	(21.48 , 25.85)
		volume	36	4.40	(7.35, 18.50)	3.11	(1.94 , 5.57)
	Week 12	height	36	0.65	(0.74, 1.10)	0.59	(0.47 , 0.74)
		surface area	36	20.00	(29.60, 45.63)	19.21	(12.40 , 26.13)
		volume	36	4.51	(7.23, 18.58)	3.32	(1.83 , 5.82)